Bringing the fundamentals into focus…
Back to Johnson & Johnson
How Johnson & Johnson stacks up
JNJ · against 5 other Healthcare companies of similar size
Valuation
60/ 100
Above the middle of the pack.
Ranked #3 of 6 · scores higher than 60% of peers
Bars: peers in each 10-point band of the valuation score2 peers with a valuation score of 60–69, including JNJ · Click a bar to see the companies
Why valuation scores 60?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its free cash flow yield and earnings yield, which are stronger than most Healthcare peers.
- EBITDA yield is close to the peer norm. EBITDA yield: 5.4% vs peer median 3.9%
- higher earnings for the price paid: stronger than 65% of peers. Earnings yield: 3.4% vs peer median 1.4%
- more free cash flow for the price paid: stronger than 71% of peers. Free cash flow yield: 3.6% vs peer median 0.0%
Metric by metric
Position: dot = JNJ, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | JNJ | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 6 reported | 3.3% | 2.9% | 60% | 30% | |
| EBITDA yieldHigher is better · 6 reported | 5.4% | 6.3% | 20% | 50% | |
| Free cash flow yieldHigher is better · 5 reported | 3.6% | 3.8% | 25% | 20% | |
| Book yieldHigher is better · 6 reported | 13.7% | 11.5% | 80% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around JNJ| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 293.8B CHF (≈$337.9B) | 73 | 61 | |
| 2 | 337.5B USD | 67 | 48 | |
| 3 | 622.8B USD | 60 | 59 | |
| 4 | 352.3B USD | 54 | 37 | |
| 5 | 1.06T USD | 50 | 63 | |
| 6 | 479.5B USD | 49 | 53 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score